Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436)

PURPOSE: Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently demonstrated improved progression free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. The current study examined potential genetic markers associated with response and PFS in the ph...

詳細記述

保存先:
書誌詳細
主要な著者: Nathanson, Katherine L., Martin, Anne-Marie, Wubbenhorst, Bradley, Greshock, Joel, Letrero, Richard, D’Andrea, Kurt, O’Day, Steven, Infante, Jeffrey R., Falchook, Gerald S., Arkenau, Hendrik-Tobias, Millward, Michael, Brown, Michael P., Pavlick, Anna, Davies, Michael A., Ma, Bo, Gagnon, Robert, Curtis, Martin, Lebowitz, Peter F., Kefford, Richard, Long, Georgina V.
フォーマット: Artigo
言語:Inglês
出版事項: 2013
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3924894/
https://ncbi.nlm.nih.gov/pubmed/23833299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0827
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料